Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Trial Profile

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Niraparib (Primary) ; Niraparib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors TESARO
  • Most Recent Events

    • 23 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
    • 16 Mar 2017 Results published in the Investigational New Drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top